Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 5/20 | 0.42 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.42 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20964505 | 0.84 | OPRD1 (0.46) | LMNAPKMALDH1A1GAASMN1; SMN2 | |
| SCHEMBL10119262 | 0.82 | LMNA (0.61) | LMNAPKMALDH1A1GAASMN1; SMN2 | |
| SCHEMBL12518071 | 0.82 | LMNA (0.61) | LMNAPKMALDH1A1GAASMN1; SMN2 | |
| SCHEMBL12518268 | 0.74 | POLB (0.48) | LMNAPKMALDH1A1GAASMN1; SMN2 | |
| SCHEMBL8698541 | 0.72 | LMNA (0.58) | LMNAPKMALDH1A1GAASMN1; SMN2 | |
| SCHEMBL6763946 | 0.70 | CXCR3 (0.52) | LMNAPKMMEN1MAPTPABPC1 | |
| SCHEMBL8495772 | 0.70 | LMNA (0.61) | LMNAPKMALDH1A1GAASMN1; SMN2 | |
| SCHEMBL12421737 | 0.69 | XIAP (0.48) | OPRD1 | |
| SCHEMBL20964504 | 0.69 | ACE (0.44) | NMUR2NMUR1OPRD1 | |
| SCHEMBL20964443 | 0.69 | PSMB5 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220526-B2 | Neuropeptide S receptor (NPSR) agonists | RESEARCH TRIANGLE INSTITUTE (US) | 2022-01-11 | — | — | US | disclosed |
| US-20190127419-A1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | RESEARCH TRIANGLE INSTITUTE | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127419-A1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | NPSR1, GRPR, NPBWR1 | LMNA 3149/4885PKM 2570/4885ALDH1A1 4821/4885 |
| US-11220526-B2 | Neuropeptide S receptor (NPSR) agonists | NPSR1, GRPR, NPBWR1 | LMNA 3149/4885PKM 2570/4885ALDH1A1 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.